Opinions Brett Girard, CPA, CA, CFA
Bausch Health Companies Inc.BHC.TODON'T BUYApr 01, 2020
The old Valent Pharmaceutical company. When it became over-levered it struggled. He thinks there are far better opportunities in the health care space.
$21.81
Stock price when the opinion was issued
$7.41
As of May 29, 2026. Market Open.
Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
DON'T BUY
A turnaround story. They have done a good job stabilizing the company. It has a lot of debt and legal issues to resolve. The debt levels are probably still too high. They are spinning out their eyecare business which is their crown jewel. There is some more work to do before taking a position.
Jamie Murray No
Healthcare
BUY ON WEAKNESS
He likes and owns it. It is basically the old broken valiant. He likes the space and he likes the big time drugs. These stocks offer incredible value. His model price is $72.41, 122% upside. Buy it when it comes down again. Buy half on the way in.
Brian Acker, CAOwned
Healthcare
TOP PICK
He likes it because nobody likes it. It is former Valiant Pharmaceuticals and trades at 6 times cash-flow. He encourages investors to look beyond its checkered past. It has high quality recurring cash-flows in the contact lens division. Every division is growing organically. It does have a high debt load, but the trajectory of cash flow will elevate that risk. Yield 0%. (Analysts’ price target is $35.39)
Steven KoOwned
Healthcare
